Farnesyltransferase inhibitors (FTIs) suppress tumor aggressiveness in several malignancies by inhibiting Ras signaling. However, treatment of cells with a low dose of the FTI tipifarnib suppresses the expression of hypoxia‐inducible factor‐1α (HIF‐1α) and results in antitumor effects without inhibiting the Ras pathway. Although we previously reported that elevated HIF‐1α expression is associated with an aggressive phenotype in gastric cancer (GC), little is known about the antitumor effects of FTIs on GC. In this study, we examined the relationship between the antitumor effects of low‐dose tipifarnib and HIF‐1α expression in GC cells. Under normoxic conditions, HIF‐1α was expressed only in MKN45 and KATOIII cells. The inhibitory effect of tipifarnib on HIF‐1α was observed in HIF‐1α‐positive cells. Low‐dose tipifarnib had antitumor effects only on HIF‐1α‐positive cells both in vitro and in vivo. Furthermore, low‐dose tipifarnib inactivated ras homolog enriched in brain (Rheb)/mammalian target of rapamycin (mTOR) signaling and decreased intracellular reactive oxygen species (ROS) levels in HIF‐1α‐positive GC cells. Our results that the antitumor effects of low‐dose tipifarnib are at least partially mediated through suppression of mTOR signaling and HIF‐1α expression via inhibition of Rheb farnesylation and reduction in ROS levels. These findings suggest that low‐dose tipifarnib may be capable of exerting an antitumor effect that is dependent on HIF‐1α expression in GC cells. Tipifarnib may have potential as a novel therapeutic agent for HIF‐1α‐expressing GC exhibiting an aggressive phenotype.
Inflammatory processes play major roles in carcinogenesis and the progression of hepatocellular carcinoma (HCC) derived from non-alcoholic steatohepatitis (NASH). But, there are no therapies for NASH-related HCC, especially focusing on these critical steps. Previous studies have reported that farnesyltransferase inhibitors (FTIs) have anti-inflammatory and anti-tumor effects. However, the influence of FTIs on NASH-related HCC has not been elucidated. In hepatoblastoma and HCC cell lines, HepG2, Hep3B, and Huh-7, we confirmed the expression of hypoxia-inducible factor (HIF)-1α, an accelerator of tumor aggressiveness and the inflammatory response. We established NASH-related HCC models under inflammation and free fatty acid burden and confirmed that HIF-1α expression was increased under both conditions. Tipifarnib, which is an FTI, strongly suppressed increased HIF-1α, inhibited cell proliferation, and induced apoptosis. Simultaneously, intracellular interleukin-6 as an inflammation marker was increased under both conditions and significantly suppressed by tipifarnib. Additionally, tipifarnib suppressed the expression of phosphorylated nuclear factor-κB and transforming growth factor-β. Finally, in a NASH-related HCC mouse model burdened with diethylnitrosamine and a high-fat diet, tipifarnib significantly reduced tumor nodule formation in association with decreased serum interleukin-6. In conclusion, tipifarnib has anti-tumor and anti-inflammatory effects in a NASH-related HCC model and may be a promising new agent to treat this disease.
It is difficult to diagnose early gallbladder cancer (GBC) preoperatively; therefore, the surgical procedure for patients suspected of having this condition should be chosen with curability and invasiveness in mind. We herein present a standardized procedure for performing complete laparoscopic whole-layer cholecystectomy (LWLC) for suspected early GBC. Between January 2010 and January 2023, LWLC was performed on 44 patients with suspected early GBCs located on the peritoneal side. We devised and performed the following procedure to perform LWLC safely. Our procedure is based on the preservation of Laennec’s capsule with an appropriate transection plane using the cystic plate as an anatomical landmark. The steps of this procedure comprise (1) isolation of the cystic duct and artery with accurate dissection of the 12c and cystic duct lymph nodes and preservation of the hilar plate; (2) preemptive ligation of the cystic duct to seal off any free cancer cells floating in bile within the gallbladder; (3) excision of the entire gallbladder starting from the S4-side of the fundus to neck with preservation of Laennec’s capsule; (4) definitive visual identification and transection of the cystic plate at the neck; and (5) resection of the cystic duct after placement of the gallbladder in an organ bag to prevent intraperitoneal dissemination of bile. Pathological examination revealed 15 GBCs (34.1%), of which 13 cases were early stage (86.7%). Specifically, the depth of invasion was in situ in four cases, mucosa in four cases, muscle propria in five cases, and subserosa in two cases. Regarding lymph node metastasis, it was detected in only one case, which had tumor invasion of the subserosa. The median operation time was 138 minutes, and estimated blood loss was 27 mL (range: 0-108 mL). There was no intraoperative bile leakage and no postoperative complications requiring surgical, endoscopic, or radiological intervention. We confirmed elastic fibers covering the outer layer of subserosa at the level of dissection from the liver bed. With a median follow-up of 56 months, 14 patients remain alive without recurrence, and one has died from another disease. Our original procedure of LWLC is a reproducible and feasible means of treating early or suspected GBC located on the free peritoneal side, achieving lengthy remission, being less invasive than other currently performed procedures, and possibly being curative.
Dendritic cells (DCs) are known to be major antigen-presenting cells, and lymph nodes (LNs) play an important role in DC-mediated immune response. CD1a is known as a marker of monocyte-derived DCs. The present study focused on the infiltration of CD1a-positive DCs (CD1a-DCs) into regional LNs in 70 cases of gallbladder cancer (GBC). After univariate analyses, the results showed that LN infiltration by CD1a-DCs was associated with unfavorable clinical outcomes in patients with GBC, with all cases categorized in the CD1a-DCs high group had nodal metastasis. LN infiltration by CD1a-DCs was not an independent prognostic factor identified by multivariate analyses. After subgroup analyses of cases with LN metastasis (n = 32), no significant impacts of CD1a-DCs infiltration into metastatic LNs were observed. In contrast, CD1a-DCs infiltration into primary tumors had a significant impact on surgical outcomes. The results of strong confounding between CD1a-DCs and LN metastasis support the theory that CD1a-DCs are developed from monocytes at tumor sites. As the results of previous research focused on CD1a-DCs infiltration into regional LNs of other organs varied, the role and significance of CD1a-DCs infiltration in regional LNs may be different according to the tumor histology or its primary site. Thus, further studies are needed to clarify the role and significance of CD1a-DCs infiltration into regional LNs of solid cancers.
Hypoxia-inducible factor-1 (HIF-1) enhances cancer cell survival in hypoxic conditions. The ketogenic diet (KGD), characterized by low-carbohydrate and high-fat intake, has been widely used for epilepsy treatment and reported to have antitumor potential. However, its impact on hypoxic cancer cells remains poorly understood. This study examined the effects of combining the HIF-1α inhibitor YC-1 with the KD formula KetoCal® on hypoxic hepatocellular carcinoma (HCC) cells. In vitro, HIF-1α knockdown (KD) and scramble control (SC) Hep3B and HepG2 cells were treated with palmitic acid (PA) and/or β-hydroxybutyrate (BOH) to mimic the KGD environment. PA significantly induced cell death and reactive oxygen species (ROS) in hypoxic KD cells, and this effect was further enhanced by BOH. Gene expression analysis indicated that HIF-1 suppresses fatty acid oxidation (FAO) and ketolysis under hypoxia. In vivo, Hep3B cells were implanted into mice fed KetoCal® with or without YC-1. KetoCal® elevated serum BOH and free fatty acids (FFAs), suppressed tumor growth, and increased intra-tumoral acetyl-CoA, ROS, and apoptosis in YC-1-treated tumors. These findings suggest that YC-1 combined with KetoCal® reactivates FAO and ketolysis, promoting acetyl-CoA accumulation and lethal ROS production in hypoxic HCC. This strategy may offer a novel preclinical model for targeting hypoxic tumors.
20 April 2024 in Clinical Journal of Gastroenterology